期刊
ANTIVIRAL RESEARCH
卷 108, 期 -, 页码 56-64出版社
ELSEVIER
DOI: 10.1016/j.antiviral.2014.05.008
关键词
JEV; Lentiviral shRNA; Antiviral; Inflammatory response; In vitro and in vivo
资金
- National Special Research Programs for Non-Profit Trades, Ministry of Agriculture [200803015, 201203082]
- National Special Research Programs for Cultivating New Transgenic Organisms, Ministry of Agriculture [2009ZX08006-007B]
Japanese encephalitis virus, a serious mosquito-borne flavivirus, causes acute encephalitis in humans and many animals, with a high fatality rate. RNA interference is a reasonable antiviral mechanism for target gene silencing. In this study, four lentiviral shRNAs (LV-E1, LV-E2, LV-NS3 and LV-NS4b) were constructed. The results showed that four recombinant lentiviruses suppressed JEV replication in vitro. Through treatment with LV-E1 or LV-E2, the TCID50 values were reduced by 10(3)-fold during 120 h post-challenge; the relative expression of viral mRNA was <7% or 13% in mouse and human neuroblastoma cells. Lentiviral shRNAs displayed robust inhibitory activity in various cells and against different genotypes of JEV. In vivo, pre-treatments of LV-E1 or LV-E2 resulted in no viral particles being observed in suckling mice brain sections. For 21 days of observation, 100% of mice were protected against lethal JEV injection by two pre-treatments with LV-E1 or LV-E2; the survival of the mice pre-challenged with lethal JEV was 88.3%/66.7% by treatment with LV-E1 or LV-E2. LV-E1 and LV-E2 suppressed the induction of inflammatory mediators effectively in neuroblastoma cells and mice. Lentiviral shRNAs significantly inhibit JEV infection for long-term in vitro and in vivo and effectively reduce the inflammatory response and relieve encephalitis symptoms, highlighting the feasibility of using lentivirus-mediated RNAi for potential therapy in JEV infection. (C) 2014 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据